Abstract
Despite its low incidence, peritoneal mesothelioma manifests with nonspecific symptoms, often leading to delayed diagnosis. Diagnosis relies on imaging techniques, histopathological evaluation, and immunohistochemistry, with emerging molecular markers refining diagnostic accuracy. The cornerstone of treatment is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, tailored to individual tumor characteristics and patient factors. Future directions involve targeted therapies and immunomodulatory agents, emphasizing multidisciplinary collaboration and translational research. This review aims to enhance understanding and optimize management, ultimately improving outcomes for affected individuals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.